Open AccessSildenafil Treatment in Heart Failure With Preserved Ejection Fraction
Author(s) -
Hanghang Wang,
Kevin J. Anstrom,
Olga Ilkayeva,
Michael J. Muehlbauer,
James R. Bain,
Steven E. McNulty,
Christopher B. Newgard,
William E. Kraus,
Adrian F. Hernandez,
G. Michael Felker,
Margaret M. Redfield,
Svati H. Shah
Publication year - 2017
Publication title -
jama cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.108
H-Index - 63
eISSN - 2380-6591
pISSN - 2380-6583
DOI - 10.1001/jamacardio.2017.1239
Subject(s) - medicine , ejection fraction , heart failure , sildenafil , cardiology
Phosphodiesterase-5 inhibition with sildenafil compared with a placebo had no effect on the exercise capacity or clinical status of patients with heart failure with preserved ejection fraction (HFpEF) in the PhosphodiesteRasE-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure with Preserved Ejection Fraction (RELAX) clinical trial. Metabolic impairments may explain the neutral results.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom